NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
MIT Introduces Interactive AI System for Fast Medical Image Annotation
MIT researchers have developed MultiverSeg, an interactive AI tool enabling efficient, user-driven segmentation of biomedical image datasets without prior model training.
•EurekAlert
Study Finds Gaps in FDA Safety Reporting for AI Medical Devices
A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
•EurekAlert
UCLA Unveils Light-Based AI System for Energy-Efficient Image Generation
Researchers at UCLA have developed an optical generative AI model that creates images using minimal energy and computational steps.